Abbott Molecular Inc.

Mayo Foundation for Medical Education and Research

Ekaterina Pestova

Larry E Morrison

Ying Zhang

Irina A Sokolova

John C Russell

Tracey L Colpitts

Kevin C Halling

Jing Du

Ping Liu

Klara Abravaya

Dimitri Semizarov

Xin Lu

Susan S Jewell

Kimberly Wilber-Mader

Adam Koch

Jesse S Voss

Benjamin Kipp

Gregory Gores

Lewis Roberts

Emily Barr Fritcher

Mona Stein Legator

Neeraj Adya

Lisa M Peterson

Madhuri Lucas

Pedram Gerami

Carl Slenk

Gu Li

Kevin Halling

Irina Sokolova

Lisa Peterson

Jesse Voss

Methods of distinguishing and identifying a patient with aggressive/indolent, prostatic adenocarcinoma comprising contacting a sample from the patient with a set of detectably labeled probes under hybridization conditions and determining the presence of chromosomal abnormalities in the sample; sets of probes for use in such methods; and kits comprising a set of probes and instructions for distinguishing or identifying a patient as having aggressive/indolent, prostatic adenocarcinoma.

Materials and methods for assessing progression of prostate cancer

The methods and compositions described herein address the need for diagnostic method that could be offered to women during yearly checkups to allow for early detection, diagnosis and classification, and treatment of endometrial cancer. In addition, these methods and compositions address the current need for improving diagnostic accuracy of biopsy procedures in symptomatic patients.

Detection of chromosomal abnormalities associated with endometrial cancer

Disclosed herein are hybridization buffer compositions and hybridization compositions, methods of making the compositions, and methods of using the compositions, such as the hybridization of DNA or RNA sequences by fluorescence in situ hybridization ('FISH').

Hybridization buffers

Compositions of nucleic acid hybridization probes for detecting a nucleic acid target sequence and methods for their production are described. In one preferred embodiment, the nucleic acid hybridization probe includes a hybridization domain, an adaptor, a linker, and a signaling domain. The hybridization domain includes a nucleic acid sequence having complementarity to the nucleic acid target sequence. The adaptor is a nucleic acid sequence. The linker includes a moiety having at least one abasic site, such that the moiety blocks extension by an elongating polymerase on a nucleic acid template containing the moiety. The signaling domain comprises a nucleic acid having at least one label or a nucleic acid having at least one nucleic acid domain for binding at least one additional nucleic acid.

Nucleic acid hybridization probes

A method to detect prostate cancer comprising contacting a sample of prostate cells from the patient with a set of detectably labeled probes under hybridization conditions and determining the presence of chromosomal abnormalities in prostate tumor tissue, PIN (intra-epithelial neoplasia), histologically benign tissue and benign prostatic hyperplasia (BPH); a method to combine immunofluorescence and FISH (IF-FISH) to facilitate the assessment of chromosomal abnormalities; a set of probes; and a kit comprising the set of probes and instructions for diagnosing prostate cancer in a patient.

Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

Methods, probes and kits for diagnosing malignant melanoma and prognosing metastasis thereof in a patient.

Methods for the analysis of spitz tumor samples

The present invention relates to compositions and methods for detection, analysis, and treatment of nucleic acids. In particular, the present invention relates to compositions and methods for generating and using hybridization probes.

Hybridization probes and methods

The methods and compositions described herein address the need for a diagnostic method that can be provided to patients with early stage lung cancer, especially non-small cell lung cancer (NSCLC), to determine whether the patient is at increased risk of poor disease outcome. The methods and compositions thus allow for more informed treatment decisions for the early stage lung cancer patient.

Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer

A method of detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract or inferring an increased risk thereof, comprising obtaining a sample of pancreatobiliary cells from a patient with a set of detectably labeled probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16 under hybridization conditions and determining the presence of chromosomal abnormalities; a set of probes comprising a locus-specific probe for MCL1, a locus-specific probe for EGFR, a locus-specific probe for MYC, and a locus-specific probe for P16; and a kit comprising the set of probes and instructions for detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract, or inferring an increased risk thereof, in a patient.

Materials and methods for diagnosis, prognosis, monitoring of recurrence, and assessment of therapeutic/prophylactic treatment of pancreatobiliary cancer

Growing community of inventors

Glenview, IL, United States of America

Ekaterina Pestova